急性心肌梗死患者经皮冠状动脉内介入治疗术后不同抗血小板治疗方案的临床疗效  

Clinical efficacy of different antiplatelet treatment schemes after acute myocardial infarction patients with percutaneous coronary intervention therapy

作　　者：杨成念 王瑛 YANG Chengnian;WANG Ying(Department of Cardiovascular Medicine,Chongqing Southeast Hospital,Chongqing,401336,China;Department of General Medicine,Chongqing Southeast Hospital,Chongqing,401336,China)

机构地区：[1]重庆市东南医院心血管内科,重庆401336 [2]重庆市东南医院全科医学科,重庆401336

出　　处：《当代医学》2022年第23期112-115,共4页Contemporary Medicine

摘　　要：目的探讨急性心肌梗死患者经皮冠状动脉内介入治疗术(PCI)后不同抗血小板治疗方案的临床疗效。方法选取2019年6月至2021年3月于本院诊断为急性心肌梗死的68例患者作为研究对象,按照治疗方法不同分为对照组(n=32)与实验组(n=36)。两组均行PCI术,术后,实验组给予阿司匹林+替格瑞洛治疗,对照组给予阿司匹林+氯吡格雷治疗,比较两组临床疗效及不良事件发生情况。结果实验组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。实验组不良事件发生率低于对照组,但差异无统计学意义。结论急性心肌梗死患者PCI术后给予替格瑞洛+阿司匹林治疗效果显著,不会增加患者不良事情发生率,临床疗效显著,值得临床推广应用。Objective To explore the clinical efficacy of different antiplatelet treatment schemes after acute myocardial infarction patients with percutaneous coronary intervention therapy(PCI).Methods 68 patients with acute myocardial infarction from June 2019 to March 2021 were selected as the research subjects,and they were divided into control groups(n=32)and experimental groups(n=36)according to different treatment methods.Both groups performed PCI.After surgery,the experimental team gave aspirin+dignirlolo treatment,the control group was given aspirin+clopidogrera treatment.The clinical efficacy and adverse events between the two groups were compared.Results The total efficiency of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse events in the experimental group was lower than the control group,but the difference was not statistically significant.Conclusion The effect of ticagrelor+aspirin in the treatment of patients with acute myocardial infarction after PCI is remarkable,and it does not increase the incidence of adverse events,which is worthy of clinical application.

关 键 词：急性心肌梗死 经皮冠状动脉内介入治疗术 抗血小板治疗 

分 类 号：R542.22[医药卫生—心血管疾病]